LDS/Medical Tests/Coagulation Factor IX Inhibitor Assay, Plasma

Coagulation Factor IX Inhibitor Assay, Plasma

Factor IX (FIX), also known as Christmas factor, is a vitamin K–dependent coagulation protein that plays a critical role in the intrinsic pathway of coagulation. Deficiency of factor IX results in hemophilia B, an X-linked inherited bleeding disorder characterized by variable severity depending on residual factor activity. In a subset of patients with hemophilia B, particularly those with severe disease and null F9 gene mutations, neutralizing antibodies (inhibitors) against factor IX may develop following exposure to exogenous factor IX concentrates.

Factor IX inhibitors bind to and inactivate infused or endogenous factor IX, leading to reduced efficacy of replacement therapy and increased risk of bleeding. Inhibitor development in hemophilia B is less common than in hemophilia A but is often associated with severe clinical complications, including allergic reactions, anaphylaxis, and nephrotic syndrome. Rarely, factor IX inhibitors may also occur as acquired autoantibodies in individuals without congenital hemophilia.

Laboratory findings typically demonstrate reduced factor IX activity that fails to correct in mixing studies, prompting evaluation for an inhibitor. The Factor IX Inhibitor Assay is used to detect and quantify inhibitory antibodies directed against factor IX, most commonly using a Bethesda-type assay, and plays a critical role in guiding therapeutic decisions and monitoring immune tolerance or immunosuppressive therapy.

  • Used to detect and quantify factor IX inhibitors in patients with hemophilia B who demonstrate reduced response to replacement therapy
  • Helpful in the evaluation of prolonged activated partial thromboplastin time (aPTT) with reduced factor IX activity that does not correct on mixing studies
  • Assists in the diagnosis of acquired factor IX inhibitors in patients without a prior history of hemophilia

A positive result indicates the presence of a neutralizing antibody to factor IX, with inhibitor strength typically reported in Bethesda units (BU). Higher inhibitor titers are associated with reduced response to factor IX replacement therapy and increased bleeding risk. Results should be interpreted in conjunction with factor IX activity levels, aPTT, mixing study results, clinical history, and treatment status.

A negative result suggests that reduced factor IX activity is due to deficiency rather than inhibitor-mediated inactivation. Clinical correlation is essential, particularly in patients receiving factor replacement or bypassing agents.

Adults: 65-180%

Normal newborn infants or healthy premature infants may have decreased levels (> or =20%)

Clot-based inhibitor assay performed using patient plasma incubated with normal pooled plasma, followed by measurement of residual factor IX activity using an activated partial thromboplastin time (aPTT)–based clotting assay. Inhibitor activity is quantified using a Bethesda or Nijmegen-modified Bethesda method.

Platelet-poor plasma on 3.2% sodium citrate (Light-blue top) vial, 1 mL minimum. 

Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or ideally, at or below -40 degrees C.

Patient must not be receiving warfarin or heparin therapy. 

Stability

  • Ambient: unfavorable
  • Refrigerated: unfavorable
  • Frozen: 28 days
Factor IX activity assay, aPTT, mixing studies, Bethesda assay confirmation, factor VIII inhibitor testing if clinically indicated, PT, CBC, liver function testing, and F9 gene mutation analysis.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login